News - Neurological, Pharmaceutical

Filter

Popular Filters

1 to 25 of 773 results

Varenicline combined with nicotine patch improves smoking cessation rates

Varenicline combined with nicotine patch improves smoking cessation rates

09-07-2014

Combining the smoking cessation medication varenicline with nicotine replacement therapy was more effective…

ChantixNeurologicalNicotinePfizerPharmaceuticalResearchSmoking cessationUSAVarenicline

AcelRx and Grunenthal file for EU approval of Zalviso

AcelRx and Grunenthal file for EU approval of Zalviso

07-07-2014

USA-based AcelRx Pharmaceuticals revealed this morning that its partner, family-owned German drugmaker…

AcelRxEuropeGrunenthalNeurologicalPharmaceuticalRegulationZalviso

Teva files citizen petition with FDA regarding Copaxone complexity

Teva files citizen petition with FDA regarding Copaxone complexity

03-07-2014

Teva Pharmaceutical Industries says it has filed a citizen petition regarding the approvability of purported…

CopaxoneLegalNeurologicalPatentsPharmaceuticalRegulationTeva Pharmaceutical IndustriesUSA

FDA orphan status for Insys’ cannabidiol as treatment for Dravet syndrome

FDA orphan status for Insys’ cannabidiol as treatment for Dravet syndrome

03-07-2014

US specialty pharma firm Insys Therapeutics yesterday revealed that the US Food and Drug Administration…

cannabidiolInsys TherapeuticsNeurologicalPharmaceuticalRare diseasesRegulationUSA

US FDA delays Allergan’s Semprana decision, approves Ozurdex

US FDA delays Allergan’s Semprana decision, approves Ozurdex

01-07-2014

US drugmaker Allergan, the subject of a hostile $53 billion takeover pursuit by Canada’s Valeant Pharmaceuticals…

AllerganBimatoprost Ophthalmic Solution 0.03% for GlaLevadexNeurologicalOphthalmicsOzurdexPharmaceuticalRegulationResearchSempranaUSA

Eisai’s Zebinix shown to be effective and well-tolerated

Eisai’s Zebinix shown to be effective and well-tolerated

30-06-2014

Once-daily Zebinix (eslicarbazepine acetate) from Japanese drug major Eisai is effective, retained and…

EisaiEuropeNeurologicalPharmaceuticalResearchZebinix

Lundbeck's desmoteplase misses primary endpoint in Ph III stroke study

28-06-2014

Danish CNS specialist Lundbeck (LUND: CO) released disappointing initial headline conclusions from DIAS-3,…

desmoteplaseLundbeckNeurologicalPharmaceutical

US psychiatrists’ views on prescribing Otsuka/Lundbeck’s brexpiprazole

26-06-2014

Surveyed US psychiatrists are receptive to novel adjunctive therapies to antidepressants for treatment-resistant…

brexpiprazoleBrintellixLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Brintellix meets primary efficacy end-point in depression study

Brintellix meets primary efficacy end-point in depression study

26-06-2014

Danish CNS drug specialist Lundbeck has announced results of the SOLUTION trial conducted in Asian patients…

BrintellixDenmarkLundbeckNeurologicalPharmaceuticalResearch

US orphan status for Insys Therapeutics’ cannabidiol for rare form of epilepsy

US orphan status for Insys Therapeutics’ cannabidiol for rare form of epilepsy

25-06-2014

US specialty pharma firm Insys Therapeutics says that the US Food and Drug Administration has granted…

cannabidiolInsys TherapeuticsNeurologicalPharmaceuticalRare diseasesRegulationUSA

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

Rilutek patent expiry to cause negative growth in ALS treatment market by 2018

25-06-2014

The amyotrophic lateral sclerosis (ALS) treatment market value will decline from $64 million in 2013…

EuropeJapanMarkets & MarketingNeurologicalPatentsPharmaceuticalRilutekSanofiUSA

Shire gets positive ruling on Vyvanse patents from US district court

25-06-2014

Ireland-headquartered drugmaker Shire, which is defending itself from a $46 billion unsolicited bid from…

ActavisAmneal PharmaLegalMylanNeurologicalPatentsPharmaceuticalRoxaneSandozShireUSAVyvanse

Positive Ph III results with Forest Labs’ vilazodone in GAD

24-06-2014

US drugmaker Forest Laboratories has released positive top-line results from three Phase III trials evaluating…

Forest LaboratoriesNeurologicalPharmaceuticalResearchvilazodone

Lundbeck to complete Chelsea Thera acquisition today

Lundbeck to complete Chelsea Thera acquisition today

23-06-2014

Danish CNS specialist Lundbeck says that it has completed the tender offer to buy all of the outstanding…

Chelsea TherapeuticsLundbeckMergers & AcquisitionsNeurologicalNortheraPharmaceutical

Roche partners in new company for MS research

Roche partners in new company for MS research

23-06-2014

Swiss drug major Roche has entered into an exclusive partnership with Inception Sciences, a drug discovery…

Inception 5Inception SciencesMergers & AcquisitionsNeurologicalPharmaceuticalResearchRocheVersant Ventures

UK Prime Minister announces drive to discover new dementia drugs in £100 million campaign

UK Prime Minister announces drive to discover new dementia drugs in £100 million campaign

19-06-2014

The UK Prime Minister David Cameron will today pledge a new drive by the UK to discover new drugs and…

DementiaNeurologicalPharmaceuticalResearchUK

GW shares rise on positive Epidiolex efficacy data

GW shares rise on positive Epidiolex efficacy data

18-06-2014

UK-based GW Pharmaceuticals has announced physician reports of efficacy and safety data from its investigational…

epidiolexGW PharmaceuticalsNeurologicalPharmaceuticalResearchUK

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

17-06-2014

Danish CSN drug specialist Lundbeck has presented results about sexual functioning from a head-to-head…

BrintellixEscitalopram OxalateLundbeckMen's HealthNeurologicalPharmaceuticalResearch

Merck pulls out of license deal with Ono Pharma for MS drug ceralifimod

Merck pulls out of license deal with Ono Pharma for MS drug ceralifimod

17-06-2014

German drug major Merck KGaA revealed this morning that, by mutual agreement, it has terminated its licensing…

ceralifimodLicensingMerck KGaAMerck SeronoNeurologicalOno PharmaceuticalPharmaceutical

Lundbeck’s Brintellix shows efficacy in cognitive function study

Lundbeck’s Brintellix shows efficacy in cognitive function study

16-06-2014

Danish CNS drug specialist Lundbeck has announced results from the CONNECT study showing that Brintellix…

BrintellixDenmarkDepressionLundbeckNeurologicalPharmaceuticalResearch

Review of ibuprofen medicines started by EMA Pharmacovigilance unit

Review of ibuprofen medicines started by EMA Pharmacovigilance unit

16-06-2014

At its June 2014 meeting, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee…

EuropeibuprofenInflammatory diseasesNeurologicalPharmaceuticalRegulation

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

12-06-2014

Ireland-headquartered drugmaker Shire says it has agreed to a written request by the US Food and Drug…

NeurologicalPharmaceuticalRegulationResearchShireUSAVyvanse

Grunenthal tests innovative treatment in one of the largest clinical trials in cancer pain

Grunenthal tests innovative treatment in one of the largest clinical trials in cancer pain

10-06-2014

German family-owned drugmaker Grunenthal is investigating the efficacy and safety of the new analgesic…

cebranopadolGrunenthalMorphineNeurologicalOncologyPharmaceuticalResearch

1 to 25 of 773 results

Back to top